Long-term outcome of transcatheter subsegmental and segmental arterial chemoemobolization using lipiodol for hepatocellular carcinoma
| Autor: | Hideo Uchida, Satoshi Takaki, Hiroshi Sakaguchi, Masayoshi Inoue, Satoru Sueyoshi, Kimihiko Kichikawa, Teruyuki Hidaka, Hiroshi Anai, Kengo Morimoto, Kiyosei Yamamoto, Toshihiro Tanaka, Hideyuki Nishiofuku, Takeshi Nagata |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Diagnostic Imaging Male medicine.medical_specialty Carcinoma Hepatocellular Antineoplastic Agents Oral cavity Neoplasm Recurrence Ethiodized Oil Carcinoma medicine Humans Radiology Nuclear Medicine and imaging Chemoembolization Therapeutic Transcatheter arterial chemoembolization Survival rate Aged Aged 80 and over business.industry Liver Neoplasms Middle Aged medicine.disease digestive system diseases Survival Rate stomatognathic diseases Treatment Outcome Hepatocellular carcinoma Antineoplastic Drugs Lipiodol Female Radiology Neoplasm Recurrence Local Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Cardiovascular and interventional radiology. 35(3) |
| ISSN: | 1432-086X |
| Popis: | To clarify the efficacy of transcatheter hepatic sub-subsegmental, subsegmental, and segmental arterial chemoembolization using lipiodol (subseg/seg lip-TACE) for hepatocellular carcinoma (HCC), long-term outcomes of patients who had been treated using subseg/seg lip-TACE alone were retrospectively examined.Subjects comprised 199 patients with HCC (T1/2/≥3=30/108/61; Child-Pugh A/B/C=115/52/32; Japan Integrated Staging [JIS] score≤1/2/≥3=88/64/47) who underwent subseg/seg lip-TACE using lipiodol mixed with an anticancer drug followed by injection of gelatin sponge particles. Each patient was followed-up every 3 months, and repeat subseg/seg lip-TACE and/or conventional lip-TACE was performed in cases showing recurrence. One-, 3-, 5-, 7-, and 10-year cumulative survival rates were calculated. Subgroup analyses were performed by stratifying the population according to T-factor, Child-Pugh classification, and JIS score.Median duration of follow-up was 3.8 years (range 0.2 to 16.4). Median overall survival was 3.8 years. One-, 3-, 5-, 7- and 10-year survival rates were 91.5, 66.1, 38.8, 20.3, and 9.4% for all patients, and 95.5, 76.9, 51.9, 27.9 and 20.4% for patients with JIS≤1, respectively. Significant survival differences were found across two subgroups of staging systems (T2 vs. T3≤[P=0.0012] and JIS score≤1 vs. 2 [P=0.0036]).This study demonstrated that subseg/seg lip-TACE is a feasible treatment for obtaining prolonged survival in patients with localized HCC showing rich vasculature. Outcomes are influenced by both tumor stage and liver function, as seen in the best prolonged survival in patients with JIS score≤1. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink